Onxeo: Publication of the 2020 Annual Financial Report
23 Aprile 2021 - 7:37PM
Business Wire
Regulatory News:
Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First
North Copenhagen: ONXEO), a clinical-stage biotechnology company
specializing in the development of innovative drugs targeting tumor
DNA Damage response (DDR) in oncology, today announced the
publication of the Company’s 2020 annual financial report.
The 2020 annual financial report is available to the public on
the Company’s website.
About Onxeo
Onxeo (Euronext Growth Paris: ALONX, Nasdaq First North
Copenhagen: ONXEO) is a clinical-stage biotechnology company
developing innovative oncology drugs targeting tumor DNA-binding
functions through unique mechanisms of action in the sought-after
field of DNA Damage Response (DDR). The Company is focused on
bringing early-stage first-in-class or disruptive compounds from
translational research to clinical proof-of-concept, a
value-creating inflection point appealing to potential
partners.
platON™ is Onxeo’s proprietary chemistry platform of
oligonucleotides acting as decoy agonists, which generates new
innovative compounds and broaden the Company’s product
pipeline.
AsiDNA™, the first compound from platON™, is a
first-in-class, highly differentiated DNA Damage Response (DDR)
inhibitor based on a decoy and agonist mechanism acting upstream of
multiple DDR pathways. Translational research has highlighted the
distinctive properties of AsiDNA™, notably its ability to abrogate
tumor resistance to PARP inhibitors regardless of the genetic
mutation status. AsiDNA™ has also shown a strong synergy with other
tumor DNA-damaging agents such as chemotherapy and PARP inhibitors.
The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase
I study has evaluated AsiDNA™ by systemic administration (IV) in
advanced solid tumors and confirmed the active doses as well as a
favorable human safety profile. The ongoing DRIIV-1b extension
study is evaluating the safety and efficacy of AsiDNA™ at a dose of
600 mg in combination with the reference chemotherapy, carboplatin
-/+ paclitaxel, in advanced metastatic tumors. Preliminary results
from both cohorts showed good tolerability, stabilization of the
disease and an increase in treatment duration compared to previous
treatments. The ongoing REVOCAN phase 1b/2 study evaluates the
effect of AsiDNA™ on the acquired resistance to PARP inhibitor
niraparib in relapsed ovarian cancer (sponsored by Gustave Roussy).
A phase 1b/2 study, AsiDNA™ Children, will be initiated in 2021 to
evaluate the association of AsiDNA™ with radiotherapy in children
with relapsed high-grade glioma (sponsored by Institut Curie).
OX401 is a new drug candidate from platON™, optimized to
be a next-generation PARP inhibitor acting on both the DNA Damage
Response and the activation of immune response, without inducing
resistance. OX401 is undergoing preclinical proof-of-concept
studies, alone and in combination with immunotherapies.
For further information, please visit www.onxeo.com.
Forward looking statements
This communication expressly or implicitly contains certain
forward-looking statements concerning Onxeo and its business. Such
statements involve certain known and unknown risks, uncertainties
and other factors, which could cause the actual results, financial
condition, performance or achievements of Onxeo to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is
providing this communication as of this date and does not undertake
to update any forward-looking statements contained herein as a
result of new information, future events or otherwise. For a
discussion of risks and uncertainties which could cause actual
results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements,
please refer to the risk factors described in the most recent
Company’s registration document or in any other periodic financial
report and in any other press release, which are available free of
charge on the websites of the Company Group (www.onxeo.com) and/or
the AMF (www.amf-france.org).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210423005513/en/
Onxeo Valerie Leroy, Investor Relations
investors@onxeo.com +33 1 45 58 76 00
Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu
+33 1 44 71 94 98
Investor Relations / Strategic Communication Dušan
Orešanský / Emmanuel Huynh NewCap onxeo@newcap.eu +33 1 44 71 94
92